ProCE Banner Activity

CME

Expanding the Spectrum of HER2 Positivity for Precision Breast Cancer Care: Clinical Implications of HER2-Low Status

Video

In this on-demand webcast from a live symposium, Nadia Harbeck, MD, PhD Komal Jhaveri, MD and Heather McArthur, MD, MPH, discuss current guidelines for the assessment of HER2 status in advanced breast cancer, including expanding the spectrum of HER2 positivity and mastering the use and safety of novel antibody&ndash drug conjugates.

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

Released: January 19, 2023

Expiration: January 18, 2024

No longer available for credit.

Share

Faculty

Nadia Harbeck

Nadia Harbeck, MD, PhD

Full Professor
Director
Breast Center, LMU University Hospital
Ludwig-Maximilians University
Munich, Germany

Komal Jhaveri

Komal Jhaveri, MD, FACP

Associate Attending
Breast Medicine Service and Early Drug Development Service
Section Head, Endocrine Therapy Research Program
Clinical Director, Early Drug Development Service
Department of Medicine
Associate Professor of Medicine
Weill Cornell Medical College
New York, New York

Heather McArthur

Heather McArthur, MD, MPH

Associate Professor
Department of Internal Medicine
Clinical Director, Breast Cancer Program
Komen Distinguished Chair in Clinical Breast Cancer Research
UT Southwestern Medical Center
Dallas, Texas

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

AstraZeneca Pharmaceuticals

Daiichi Sankyo, Inc.

Target Audience

This educational program is intended for medical oncologists and other healthcare professionals who treat patients with gynecologic cancers.

Program Learning Goal


The goal of this activity is to improve the knowledge, confidence, and competence of learners in selecting individualized treatment regimens for patients with gynecologic malignancies.

Learning Objectives

  • Assess appropriate predictive biomarkers in gynecologic cancers to guide treatment selection and clinical trial eligibility
  • Evaluate available practice-changing clinical data on new targeted therapies as single-agent or combination therapies in cervical, endometrial, and ovarian cancers
  • Plan treatment strategies for patients with cervical, endometrial, and ovarian cancers that incorporate novel therapies and combination strategies
  • Select maintenance therapy for patients with ovarian cancer with or without BRCA mutations or other homologous recombination repair deficiencies in the frontline and relapsed settings
  • Describe the role of ICI-based therapy in endometrial cancer classified as microsatellite stable

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Faculty Disclosure

Primary Author

Nadia Harbeck, MD, PhD

Full Professor
Director
Breast Center, LMU University Hospital
Ludwig-Maximilians University
Munich, Germany

Nadia Harbeck, MD, PhD: consultant: AstraZeneca, Daiichi Sankyo, Lilly, MDS, Novartis, Pierre Fabre, Pfizer, Roche, Sandoz/Hexal, Seattle Genetics; fees for non-CME/CE services: AstraZeneca, Daiichi Sankyo, Lilly, MDS, Novartis, Pierre Fabre, Pfizer, Roche, Seattle Genetics.

Komal Jhaveri, MD, FACP

Associate Attending
Breast Medicine Service and Early Drug Development Service
Section Head, Endocrine Therapy Research Program
Clinical Director, Early Drug Development Service
Department of Medicine
Associate Professor of Medicine
Weill Cornell Medical College
New York, New York

Komal Jhaveri, MD: consultant/advisor: AbbVie, AstraZeneca, Blueprint Medicine, Bristol-Myers Squibb, Daiichi Sankyo, Eisai, Genentech/Roche, Gilead, Jounce Therapeutics, Lilly/Loxo Oncology, Menarini/Stemline, Novartis, Olema, Pfizer, Seagen, Sun Pharma, Taiho Oncology; researcher: AstraZeneca, Context Therapeutics, Debio, Genentech/Roche, Gilead, Lilly/Loxo Oncology, Merck, Novartis, Pfizer, Puma, Zymeworks.

Heather McArthur, MD, MPH

Associate Professor
Department of Internal Medicine
Clinical Director, Breast Cancer Program
Komen Distinguished Chair in Clinical Breast Cancer Research
UT Southwestern Medical Center
Dallas, Texas

Heather McArthur, MD, MPH: advisor: AstraZeneca, Bristol-Myers Squibb, Crown Bioscience, Daiichi Sankyo, Gilead Sciences, Immunomedics, Lilly, Merck, Pfizer, Puma Biotech, Seattle Genetics; researcher (paid to institution): Bristol-Myers Squibb, Merck.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Information

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 19, 2023, through January 18, 2024:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.